Literature DB >> 19162324

Is complement factor H a susceptibility factor for IgA nephropathy?

Matthew Edey1, Lisa Strain, Roy Ward, Saeed Ahmed, Trevor Thomas, Timothy H J Goodship.   

Abstract

There is substantial evidence to suggest that complement activation plays a pivotal role in the pathogenesis of IgA nephropathy. Mesangial C3 deposition is seen in approximately 90% of patients and polymeric IgA has been shown to activate the alternative and lectin pathways. In addition there have been reports of deficiency and mutations in the serum complement regulator factor H (CFH) in association with IgA nephropathy. In this study we have examined the hypothesis that CFH is a susceptibility factor for IgA nephropathy. In 46 IgA nephropathy patients we undertook genotyping of three CFH SNPS (rs3753394, rs3753396 and rs1065489). There was no significant difference in the allele frequency of these 3 SNPs between the patients and normal controls. In the same group of patients we undertook mutation screening of CFH exons 18-23 using direct sequencing and found no abnormalities. All the patients had a normal serum factor H concentration. In this small cohort of IgA nephropathy patients we have not found evidence to support the hypothesis that factor H is a major susceptibility factor for the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19162324     DOI: 10.1016/j.molimm.2008.12.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

1.  Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway.

Authors:  Lee Aun Tan; Andrew C Yang; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2011-05-15       Impact factor: 14.870

2.  A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.

Authors:  Khalil El Karoui; Gary S Hill; Alexandre Karras; Christian Jacquot; Luc Moulonguet; Olivier Kourilsky; Véronique Frémeaux-Bacchi; Michel Delahousse; Jean-Paul Duong Van Huyen; Alexandre Loupy; Patrick Bruneval; Dominique Nochy
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

3.  IgA nephropathy associated with a novel N-terminal mutation in factor H.

Authors:  Roland Schmitt; Rafael T Krmar; Anncharlotte Kristoffersson; Magnus Söderberg; Diana Karpman
Journal:  Eur J Pediatr       Date:  2010-08-24       Impact factor: 3.183

4.  Eculizumab treatment for rescue of renal function in IgA nephropathy.

Authors:  Therese Rosenblad; Johan Rebetz; Martin Johansson; Zivile Békássy; Lisa Sartz; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2014-06-13       Impact factor: 3.714

5.  Complement activation by phospholipids: the interplay of factor H and C1q.

Authors:  Lee Aun Tan; Bingbin Yu; Francis C J Sim; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2010-12-10       Impact factor: 14.870

Review 6.  Current Understanding of the Role of Complement in IgA Nephropathy.

Authors:  Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2015-02-18       Impact factor: 10.121

7.  Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy.

Authors:  Yousr Gorgi; Imen Hbibi; Imen Sfar; Tahar Gargueh; Majda Cherif; Rim Goucha Louzir; Raoudha Daghbouj; Houda Aouadi; Mouna Makhlouf; Thouraya Ben Romdhane; Salwa Jendoubi-Ayed; Mohamed Amri; Adel Kheder; Mohaled R Lakhoua; Taïeb Ben Abdallah; Khaled Ayed
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-03-30

8.  Factors influencing treatment of atypical hemolytic uremic syndrome.

Authors:  Carla M Nester; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-18       Impact factor: 10.614

Review 9.  The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Authors:  Barbora Knoppova; Colin Reily; Nicolas Maillard; Dana V Rizk; Zina Moldoveanu; Jiri Mestecky; Milan Raska; Matthew B Renfrow; Bruce A Julian; Jan Novak
Journal:  Front Immunol       Date:  2016-04-12       Impact factor: 7.561

10.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.